Kindred Companion Sciences said it bred two beagles, Bailey and Alfie, in September 2024 using CRISPR-based precision gene editing that does not produce Can f 1, the major dog allergen present in dander or saliva. The company says the dogs were bred without the major allergen that affects people with dog allergies. That’s the headline here: a biotechnology company has pushed deeper into the machinery of life itself, turning living animals into products shaped by corporate science and regulatory lag.
The company said veterinary examinations showed both dogs are experiencing normal growth and development, even though the FDA has not yet approved the company's gene-editing tools. That gap matters. The work moved ahead first, and approval trails behind. The apparatus of oversight is still catching up to what the company already did.
USA TODAY reported the claim on Aug. 7, 2026 at 3:07 p.m. ET. The article said the work marks the first time genome editing has been used to modify dog allergens. That’s not a small tweak to breeding. It’s a direct intervention into the biology of animals to serve a market that wants the benefits of companionship without the inconvenience of allergy.
Who Gets to Edit Life
Kindred Companion Sciences said the genetic editing was conducted in accordance with U.S. federal standards for animal care and use. The company’s language is tidy, bureaucratic, and familiar. Standards, compliance, use. The words sound clean even when the underlying reality is a private company deciding what gets altered in an animal’s body and when.
The report said dog and cat allergies affect 10% to 20% of the worldwide population, citing National Institutes of Health information. It also said scientific evidence shows that no dog, cat or horse breed is completely hypoallergenic, according to a March 2024 study published by the National Institutes of Health. That matters because the market for “hypoallergenic” animals has long traded on hope, branding, and selective breeding claims that don’t erase the underlying biology.
The article quoted the company's August study as saying, “Breeds marketed as hypoallergenic do not yield consistently lower environmental exposure,” and “These approaches do not alter the underlying expression of Can f 1, which is produced from sebaceous glands and tongue epithelial tissue.” Those lines cut through the marketing. The company itself says the old approach doesn’t change the source of the allergen. So now the answer is gene editing, not restraint.
What the Market Wants
The article said sebaceous glands are oil-producing glands found on the skin, and tongue epithelial tissue is the tongue's outer layer of cells. In plain terms, the company is targeting the source material of allergy production. Not reducing demand. Not changing the conditions that make people allergic. Changing the animal.
Hypoallergenic dogs have grown in popularity in recent years, the report said. It noted that Bo and Sunny, a pair of Portuguese Water Dogs, joined the Obamas in 2009 and 2013, and that Malia Obama, President Barack Obama's eldest daughter, suffered from canine allergies. Even here, the story runs through elite households and their preferences, where access to animals, science, and comfort all sit comfortably together.
The Bigger Gene-Editing Machine
Kindred Companion Sciences’ work comes amid broader interest in editing animal genes. The article cited Colossal Biosciences, a Texas-based genetic engineering company, which announced last year that it brought the dire wolf back from extinction. The report said Colossal was able to breed three dire wolf puppies using extracted DNA from a 13,000-year-old tooth and a 72,000-year-old skull.
It said the dire wolf previously existed only 13,000 years ago, stood about 3½ feet tall and could weigh up to 150 pounds. Researchers used DNA specimens of the extinct animal to create two dire wolf genomes and compare them with other canid species, then edited 14 genes found in modern gray wolves to match specific extinct traits. Domestic dogs were then used as surrogate mothers for the wolves.
That’s the same logic, just dressed in different branding: extract, edit, reproduce, and call it progress. The company line is about allergy relief and normal development. The deeper story is about who gets to decide what life becomes, which bodies are altered, and which creatures are turned into platforms for corporate ambition.